The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
The latest readout, from the COMP006 study, showed that two doses of the highest, 25 mg dose of COMP360, given in a controlled environment with psychological support from a trained therapist, were ...
Stocktwits on MSN
CMPS stock jumps 22% pre-market as Compass sets timeline for new phase 3 depression trial results
Compass announced in January that the FDA had accepted its Investigational New Drug application for COMP360 for the treatment ...
Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.
New subscription platform brings validated nonprofit data into one workspace to save time; expands discovery beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results